PBM

Psyence Biomedical Ltd.

$3.03

0.33%

SectorHealthcareIndustryBiotechnologyCountryCanada

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Source: Yahoo Finance

Market Cap—

Dividend Yield—

Beta1.78

AI summary

Price & performance

1M-32.5%

3M+39.7%

YTD-86.8%

1Y-96.8%

52-week range—

Beta1.78

Full chart and returns against a benchmark

Q-Score

—/ 100

Quality against peers; 50 is the peer median.

Growth—

Risk4

Performance12

Valuation—

Profitability—

Leverage—

Sentiment—

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—

Net income$1M

Net margin—

Historical fundamentals

Valuation

PBMIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B—6.22PEG—4.02

Dividend yield—

Every valuation metric

Historical Fundamentals

Net Income

P/E

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q3 2025	vs a year before
Net Income	$1M	—	-$753.3K	-632.4%

Q-Scores

OverallNeeds fundamentals: risk and returns alone don’t measure quality

—

Risk

Industry 554

Performance

Industry 6612

Key Metrics

Fundamentals: trailing twelve months to Sep 2025, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.780.94

Volume

IM 693.1KSM 741.7K76.9K

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/E	EV/EBITDA	P/S	P/B	FCF yield	Implied growth	Revenue growth	Op. margin	ROE	Debt/equity
PBMPsyence Biomedical Ltd.	—	—	—	—	—	—	—	—	—	-33.2%	0.0
VRTXVertex Pharmaceuticals Incorporated	$138.9B	34.9	30.5	10.7	6.6	2.3%	15.9%	10.5%	33.2%	19.0%	0.2
MRNAModerna, Inc.	$101.5B	—	—	40.2	14.8	-1.9%	—	13.1%	-116.0%	-40.8%	0.1
REGNRegeneron Pharmaceuticals, Inc.	$94.8B	19.7	17.3	5.6	2.8	4.0%	8.2%	18.6%	28.8%	14.4%	0.1
ARGXargenx SE	$61.1B	47.3	54.7	14.7	8.3	1.1%	25.0%	89.9%	25.4%	17.6%	0.0
ONCBeOne Medicines AG	$48.4B	52.9	32.2	7.3	8.3	3.0%	11.1%	32.9%	17.8%	15.7%	0.2
RVMDRevolution Medicines, Inc.	$41.8B	—	—	—	17.4	-3.5%	—	—	-853.0%	-77.9%	0.0
RPRXRoyalty Pharma plc	$39.9B	59.4	32.0	15.3	4.1	7.4%	2.9%	11.4%	57.1%	6.9%	0.9
GMABGenmab A/S	$33.3B	34.5	34.3	8.9	5.7	3.5%	11.8%	19.2%	28.6%	16.5%	0.9
Industry median		11.7	20.2	7.7	2.2	-22.3%	9.9%	12.8%	-76.9%	-60.8%	0.0
PBM percentile		—	—	—	—	—	—	—	—	72nd	39th